Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Ropeginterferon-alfa-2b

Various toxicities

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kiladjian J-J, et al. Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV). Blood 140 (Suppl.) : 9663-9664, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-156889 [abstract] Kiladjian J-J, et al. Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV). Blood 140 (Suppl.) : 9663-9664, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-156889 [abstract]
Metadaten
Titel
Ropeginterferon-alfa-2b
Various toxicities
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56563-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Fluorouracil

Case report

Cladribine

Case report

Multiple drugs

Case report

Thiamazole

Case report

Multiple drugs

Case report

Zoledronic-acid